Key Takeaways
- • Apollo Global Management acquires a stake in Swiss dental company vVardis Holding AG, valuing the business at over $1 billion in a transaction that reinforces investor confidence in regenerative dental care technologies.
- • Founders and co-CEOs Haley and Goly Abivardi retain approximately 70% ownership following Apollo's investment, maintaining significant control over the company's strategic direction.
- • vVardis's proprietary Curodont technology—a peptide-based solution enabling natural tooth remineralization—positions the company in a high-growth niche that displaces traditional invasive dental procedures with preventative and regenerative alternatives.
- • Apollo's capital will fund geographic expansion across the US and Europe, leveraging existing market penetration in American dental practices and an emerging presence in Middle Eastern markets.
- • The deal reflects sustained institutional appetite for innovative healthcare solutions, with vVardis having previously attracted backing from notable early investors including David Wertheimer and family office Duxebridge Capital.
Summary
Apollo Global Management has invested in vVardis Holding AG, a Swiss dental company specializing in non-invasive treatments for early-stage tooth decay, at a valuation exceeding $1 billion. The transaction preserves founder control, with co-CEOs Haley and Goly Abivardi maintaining approximately 70% ownership while Apollo takes a meaningful minority position to support the company's expansion strategy.
vVardis operates within a differentiated segment of the dental market through its proprietary Curodont technology, a peptide-based therapeutic designed to penetrate tooth enamel and facilitate natural remineralization. This approach offers patients and practitioners an alternative to traditional surgical drilling procedures, aligning with broader industry shifts toward preventative care and tissue regeneration over invasive interventions.
The investment capitalizes on vVardis's established foothold in key markets. The company has already built a presence across US dental practices and has begun establishing operations in the Middle East. Apollo's capital will accelerate expansion efforts across the United States and Europe, targeting increased adoption among dental practitioners and patient populations seeking restorative therapies that avoid conventional surgical approaches.
The transaction reflects growing institutional confidence in the regenerative dental care sector. vVardis has previously attracted investment from sophisticated sources including investor David Wertheimer and Duxebridge Capital, signaling consistent institutional recognition of the company's technology differentiation and market opportunity. Apollo's nine-figure commitment validates the durability of this thesis and positions vVardis for scaled market penetration during a period of heightened investor focus on healthcare innovation and alternatives to traditional treatment paradigms.
vVardis operates within a differentiated segment of the dental market through its proprietary Curodont technology, a peptide-based therapeutic designed to penetrate tooth enamel and facilitate natural remineralization. This approach offers patients and practitioners an alternative to traditional surgical drilling procedures, aligning with broader industry shifts toward preventative care and tissue regeneration over invasive interventions.
The investment capitalizes on vVardis's established foothold in key markets. The company has already built a presence across US dental practices and has begun establishing operations in the Middle East. Apollo's capital will accelerate expansion efforts across the United States and Europe, targeting increased adoption among dental practitioners and patient populations seeking restorative therapies that avoid conventional surgical approaches.
The transaction reflects growing institutional confidence in the regenerative dental care sector. vVardis has previously attracted investment from sophisticated sources including investor David Wertheimer and Duxebridge Capital, signaling consistent institutional recognition of the company's technology differentiation and market opportunity. Apollo's nine-figure commitment validates the durability of this thesis and positions vVardis for scaled market penetration during a period of heightened investor focus on healthcare innovation and alternatives to traditional treatment paradigms.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.